Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 941960 of 20,252 grants

Active NON-SBIR/STTR RPGS
Quantitative MRI to automatically delineate intraprostatic tumor for radiation therapy
NATIONAL CANCER INSTITUTE Beckman Research Institute/City of Hope United States 2024 – 2029

PROJECT SUMMARY Prostate cancer (PCa) is the most common cancer among men. Radiation therapy is an integral part of the standard of care for the treatment of PCa. Local recurrences...

$7.05M
USD
Active NON-SBIR/STTR RPGS
Discovery of Potent Selective Inhibitors of the Histone Methyltransferase SUV39H1 for the Treatment of Cancer
NATIONAL CANCER INSTITUTE Sanford Burnham Prebys Medical Discovery... United States 2024 – 2029

PROJECT SUMMARY Cancer treatment has been transformed by a class of drugs, that includes Keytruda and Opdivo, that enables the immune system to recognize and selectively kill cance...

$8.09M
USD
Active NON-SBIR/STTR RPGS
Novel estrogen receptor mutations as a biomarker dictating therapy response in advanced endocrine-resistant estrogen receptor-positive breast cancer
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2024 – 2026

PROJECT SUMMARY While there have been tremendous advances in the treatment of estrogen receptor-positive (ER+) breast cancer, late-stage ER+ metastatic breast cancer (MBC) has very...

$1.64M
USD
Active NON-SBIR/STTR RPGS
Develop a PET radiotracer suitable for in vivo imaging of TGFβ
NATIONAL CANCER INSTITUTE Providence Health & Services - Oregon United States 2024 – 2026

Project Summary/Abstract Transcription growth factor beta (TGFβ) is a pleiotropic cytokine with a significant role in creating an immunosuppressive tumor microenvironment. High lev...

$1.7M
USD
Active NON-SBIR/STTR RPGS
Targeting HMGA1 Tumor-Stromal Networks in Pancreatic Carcinogenesis
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2024 – 2029

HMGA1 Chromatin Regulators in Pancreatic Carcinogenesis ABSTRACT Background: We propose to elucidate mechanisms mediated by High Mobility Group A1 (HMGA1) chromatin regulators in p...

$4.32M
USD
Active NON-SBIR/STTR RPGS
PROSPECT: Premalignant Oral Lesions Pathology and Epigenetic Risk Prediction Tool
NATIONAL CANCER INSTITUTE Loma Linda University United States 2024 – 2029

ABSTRACTThis application validates a minimally invasive, multi-stage artificial intelligence (AI)-based cytologic, histologic andepigenetic biomarker to identify oral premalignant...

$7.11M
USD
Active NON-SBIR/STTR RPGS
Targeting Tregs in the solid tumor microenvironment by modulating metabolite signaling
NATIONAL CANCER INSTITUTE Fred Hutchinson Cancer Center United States 2024 – 2026

ABSTRACT The efficacy of cell-based immunotherapies in treating solid tumors is hampered due to challenges pertaining to infiltration, function, and persistence of CD8+ effector T...

$4.53M
USD
Active NON-SBIR/STTR RPGS
The Role of Mechanical Stress in Mitigating Side Effects of Chemotherapy
NATIONAL CANCER INSTITUTE Boise State University United States 2024 – 2027

First line platinum-based chemotherapies kill cancer cells through formation of bulky DNA adducts, however,these adducts also form in healthy tissues leading to side effects that s...

$4.25M
USD
Active NON-SBIR/STTR RPGS
Enhanced Pain Coping in Cancer (EPIC)
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2024 – 2029

PROJECT SUMMARY/ABSTRACT Chronic pain is a common symptom that affects 30-40% of cancer survivors, diminishing their quality of life, impairing physical functions, and increasing h...

$7.33M
USD
Active NON-SBIR/STTR RPGS
Intraoperative quantitative CT imaging of breast specimen for reducing re-surgery rate and tumor cataloguing
NATIONAL CANCER INSTITUTE University of Chicago United States 2024 – 2029

Project Summary/Abstract The objective of the project is to develop the world-first X-ray dual-energy cone-beam microCT (DECB µCT) dedicated to intraoperative imaging of lumpectomy...

$6.73M
USD
Active NON-SBIR/STTR RPGS
A novel pathway to overcome resistance to immunotherapy in melanoma
NATIONAL CANCER INSTITUTE Northwestern University At Chicago United States 2024 – 2029

Project Summary/Abstract Despite the progress in the treatment of advanced melanoma brought by the approval and use of immune checkpoint inhibitors (ICIs), most patients are resist...

$3.66M
USD
Active NON-SBIR/STTR RPGS
Partnering with primary care to address goals of equity, value and sustainment for primary cancer prevention
NATIONAL CANCER INSTITUTE University of Colorado Denver United States 2024 – 2029

PROJECT SUMMARY/ABSTRACT Rural-serving primary care clinics in our Colorado Implementation Science Center in Cancer Control (COISC3) seek to address inequities in behavioral cancer...

$6.63M
USD
Active NON-SBIR/STTR RPGS
Targeting cytoplasmic SET oncoprotein by sphingolipid analog drugs for the induction of necroptosis to treat lung cancer
NATIONAL CANCER INSTITUTE Medical University of South Carolina United States 2024 – 2029

SUMMARY Non-small cell lung cancer (NSCLC) remains the deadliest cancer, and novel therapeutic strategies are needed to improve treatment outcomes of patients with this disease. FT...

$3.84M
USD
Active NON-SBIR/STTR RPGS
Allosteric mechanisms driving paradoxical activation of RAF kinases
NATIONAL CANCER INSTITUTE University of Minnesota United States 2024 – 2029

ABSTRACT Mutations in the BRAF protein kinase are key drivers of melanoma, thyroid cancer, and colon cancer. Existing drugs, like vemurafenib, that target the most common BRAF muta...

$4.7M
USD
Active NON-SBIR/STTR RPGS
Mechanisms of JAG1-mediated immune suppression in the pancreatic cancer microenvironment
NATIONAL CANCER INSTITUTE Methodist Hospital Research Institute United States 2024 – 2029

Pancreatic cancer (PanCan) is notorious for its resistance to therapy including immunotherapy, which is largely contributed by a suppressive tumor microenvironment. Targeting molec...

$6.88M
USD
Active TRAINING, INDIVIDUAL
Epigenetic drivers of lung metastasis in osteosarcoma
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2024 – 2026

PROJECT SUMMARY Osteosarcoma (OS) metastasis is the leading driver of mortality, but there are no therapies tailored to metastatic disease. Despite the development of numerous trea...

$539.7K
USD
Active TRAINING, INDIVIDUAL
Generating hiPSC-derived ATRT models to investigate cell of origin and identify therapeutic vulnerabilities
NATIONAL CANCER INSTITUTE University of California, San Diego United States 2024 – 2026

Project Summary Atypical teratoid rhabdoid tumors (ATRTs) are aggressive pediatric brain cancers that lack standardized treatment regimens. After radiotherapy treatments, survivors...

$417.6K
USD
Active TRAINING, INDIVIDUAL
The frequency and function of Type 3 Innate Lymphoid Cells regulates the melanoma tumor microenvironment
NATIONAL CANCER INSTITUTE Duke University United States 2024 – 2026

Project Summary/Abstract Malignant tumors escape immune surveillance by evading, suppressing, or distorting immune function. The recent success of immune checkpoint blockade therap...

$772.8K
USD
Active NON-SBIR/STTR RPGS
Development of novel nanotherapeutics to overcome therapy resistance using canine brain tumor as a spontaneous model
NATIONAL CANCER INSTITUTE University of California At Davis United States 2024 – 2028

Title: Development of novel nanotherapeutics to overcome therapy resistance using canine brain tumor as a spontaneous model Project Summary/Abstract High-grade gliomas (HGGs), incl...

$6.35M
USD
Active TRAINING, INDIVIDUAL
Dissecting the role of the Fanconi anemia pathway in chromothripsis
NATIONAL CANCER INSTITUTE Ut Southwestern Medical Center United States 2024 – 2027

PROJECT SUMMARY/ABSTRACT Cancer-associated chromosomal abnormalities frequently arise through punctuated episodes of genomic instability. This is exemplified by chromothripsis, the...

$397.9K
USD